George Perry to Disease Progression
This is a "connection" page, showing publications George Perry has written about Disease Progression.
Connection Strength
0.547
-
Castellani RJ, Perry G. Dementia Pugilistica Revisited. J Alzheimers Dis. 2017; 60(4):1209-1221.
Score: 0.120
-
Moreira PI, Zhu X, Liu Q, Honda K, Siedlak SL, Harris PL, Smith MA, Perry G. Compensatory responses induced by oxidative stress in Alzheimer disease. Biol Res. 2006; 39(1):7-13.
Score: 0.056
-
Ashford JW, Atwood CS, Blass JP, Bowen RL, Finch CE, Iqbal K, Joseph JA, Perry G. What is aging? What is its role in Alzheimer's disease? What can we do about it? J Alzheimers Dis. 2005 Jun; 7(3):247-53; discussion 255-62.
Score: 0.054
-
Iverson GL, Gardner AJ, Shultz SR, Solomon GS, McCrory P, Zafonte R, Perry G, Hazrati LN, Keene CD, Castellani RJ. Chronic traumatic encephalopathy neuropathology might not be inexorably progressive or unique to repetitive neurotrauma. Brain. 2019 Dec 01; 142(12):3672-3693.
Score: 0.037
-
Iverson GL, Keene CD, Perry G, Castellani RJ. The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features. J Alzheimers Dis. 2018; 61(1):17-28.
Score: 0.032
-
Manassero G, Guglielmotto M, Zamfir R, Borghi R, Colombo L, Salmona M, Perry G, Odetti P, Arancio O, Tamagno E, Tabaton M. Beta-amyloid 1-42 monomers, but not oligomers, produce PHF-like conformation of Tau protein. Aging Cell. 2016 10; 15(5):914-23.
Score: 0.029
-
Mondrag?n-Rodr?guez S, Perry G, Luna-Mu?oz J, Acevedo-Aquino MC, Williams S. Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome. Neuropathol Appl Neurobiol. 2014 Feb; 40(2):121-35.
Score: 0.024
-
Johnston JM, Hu WT, Fardo DW, Greco SJ, Perry G, Montine TJ, Trojanowski JQ, Shaw LM, Ashford JW, Tezapsidis N. Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res. 2014 Feb; 11(2):165-74.
Score: 0.024
-
Nunomura A, Tamaoki T, Motohashi N, Nakamura M, McKeel DW, Tabaton M, Lee HG, Smith MA, Perry G, Zhu X. The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons. J Neuropathol Exp Neurol. 2012 Mar; 71(3):233-41.
Score: 0.021
-
Bonda DJ, Wang X, Perry G, Smith MA, Zhu X. Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies. Drugs Aging. 2010 Mar 01; 27(3):181-92.
Score: 0.019
-
Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, Lerner A, Tabaton M, Perry G, Smith MA. Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study. Exp Gerontol. 2010 Jan; 45(1):47-52.
Score: 0.018
-
Mondrag?n-Rodr?guez S, Basurto-Islas G, Santa-Maria I, Mena R, Binder LI, Avila J, Smith MA, Perry G, Garc?a-Sierra F. Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int J Exp Pathol. 2008 Apr; 89(2):81-90.
Score: 0.016
-
Webber KM, Perry G, Smith MA, Casadesus G. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res. 2007 Oct; 5(3):177-83.
Score: 0.016
-
Petersen RB, Nunomura A, Lee HG, Casadesus G, Perry G, Smith MA, Zhu X. Signal transduction cascades associated with oxidative stress in Alzheimer's disease. J Alzheimers Dis. 2007 May; 11(2):143-52.
Score: 0.015
-
Lam-Himlin D, Espey MG, Perry G, Smith MA, Castellani RJ. Malignant glioma progression and nitric oxide. Neurochem Int. 2006 Dec; 49(8):764-8.
Score: 0.015
-
Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol. 2006 Jul; 65(7):631-41.
Score: 0.014
-
Sparks DL, Friedland R, Petanceska S, Schreurs BG, Shi J, Perry G, Smith MA, Sharma A, Derosa S, Ziolkowski C, Stankovic G. Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging. 2006 Jul-Aug; 10(4):247-54.
Score: 0.014
-
Zhu X, Ogawa O, Wang Y, Perry G, Smith MA. JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. J Neurochem. 2003 Apr; 85(1):87-93.
Score: 0.012
-
Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001 Aug; 60(8):759-67.
Score: 0.010